At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories
- Mechanism of Action Interleukin 8 receptor antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 04 Feb 2008 Discontinued - Preclinical for Inflammatory bowel disease in USA (PO)
- 09 Jun 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Inflammatory Bowel Disorders pharmacodynamics section
- 31 Dec 2001 Preclinical development for Inflammatory bowel disease in USA (PO)